CE InformationDownload MaterialsCourse Progress
  • Access Webinar
  • Evaluation
  • Certificate
Evaluation

Targeting IL-23 in IBD: Updates in Emerging Therapies and Patient-Centered Care

Evaluation

HMP Education would appreciate your feedback on the quality and impact of this activity.

Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little).

To what extent are you able to better achieve each of the following learning objectives?

Evaluate current challenges in IBD treatment including the need for novel targeted strategies
Describe the mechanism of action of IL-23 in IBD pathogenesis and their utility in clinical practice
Assess the safety and efficacy of current and emerging IL-12/23 and IL-23 inhibitors as well as key considerations and real-world evidence for their optimal use and sequencing in IBD treatment
Outline strategies to address patient needs and provide individualized care through consistent communication and shared decision-making

Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor).

Raymond K. Cross, Jr., MD, MS, AGAF, FACG
Aline Charabaty, MD
David P. Hudesman, MD, FACG, AGAF

Please rate the following components relating to this activity:

Content
Relevance to your practice 
Educational format 
Audience-participation portions (eg., Q&A, polling, pre/post-testing) 
Resources and/or other materials supporting the activity
Overall

Therapeutic recommendations presented in this activity did not encourage inappropriate or excessive use of products/devices.
How many patients do you encounter with Crohn's Disease and Ulcerative Colitis on a weekly basis?

Do you feel like there were any new data presented?

Did you learn anything new?

Did you gain confidence on the new information?

Did this program include opportunities to learn as a part of a healthcare team?
According to current data, approximately what percentage of patients are primary non-responders?
Which of the following cytokines promotes the induction of a Th17 immune response and the production of inflammatory cytokines involved in IBD pathogenesis?
Data from the SUCCESS consortium demonstrated that bio-naïve IBD patients treated with _______, saw higher rates of clinical and endoscopic remission.
A comparative safety cohort study demonstrated that ustekinumab treatment was associated with a lower risk of which AE, compared to TNF-a antagonists?
How confident are you now in your ability to utilize shared decision-making strategies to individualize patient care?

Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific.
What challenges or barriers outside of your control may prevent you from changing your practice?
255 characters max

The information presented in this activity did not serve to advance a proprietary interest of any commercial entity.
Based on my participation in this activity, I anticipate I will more often (select all that apply):